ClinicalTrials.Veeva

Menu

Prospective Clinical Follow-up After the Percutaneous Closure of a Patent Foramen Ovale (PFO-HUG)

University Hospitals (UH) logo

University Hospitals (UH)

Status

Unknown

Conditions

Foramen Ovale, Patent
Stroke

Study type

Observational

Funder types

Other

Identifiers

NCT01149447
PFO-HUG-Study

Details and patient eligibility

About

Following a cryptogenic stroke, many patients are nowadays treated with the percutaneous closure of a patent foramen ovale (PFO), assuming that the aetiology of the stroke is secondary to a paradoxical embolism. After the PFO closure procedure a dual antiplatelet regimen is often prescribed for 3-6 months and several cardiologic and neurologic follow-up exams are scheduled in the first 12 months of follow-up. Usually a transthoracic +/- transoesophageal echocardiography (TTE +/- TEE) are performed at 6 months, however this kind of control is not systematically performed. In order to improve the clinical outcomes in this young patients' population, the investigators prospectively perform a complete cardiologic and neurologic follow-up program to all patients undergoing a successful percutaneous closure of a PFO.

The aim of these controls is to confirm the good position of the PFO-device, to confirm the absence of any residual right to left shunt or any significant atrial arrhythmias Furthermore this prospective follow-up will analyze the possible mechanisms leading to a cerebral stroke recurrence (e.g. size of the PFO, presence of an atrial septal aneurysm, presence of a residual shunt, size of the utilized closure device, ....).

Full description

At follow-up the following exams will be performed:

  • at hospital discharge: chest X-ray +/- TTE + 7-days event loop record (ELR)
  • at 6 months: clinical cardiologic and neurologic examination + TTE + TEE + 7-days ELR + trans-cranial doppler (TCD) with micro bubbles detection.
  • at 1 year: clinical cardiologic and neurologic examination + TTE +/- TEE + 7-days ELR + trans-cranial doppler (TCD) with micro bubbles detection +/- cerebral MRI

Enrollment

200 estimated patients

Sex

All

Ages

18 to 90 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • 18 years old patients
  • signed informed consent
  • all consecutive patients undergoing a successful percutaneous closure of a PFO secondary to a cryptogenic stroke

Exclusion criteria

  • all patients with an alternative aetiology of the initial stroke
  • all patients in whom the percutaneous closure of the PFO is contraindicated
  • all patients with a known allergy to aspirin and or clopidogrel

Trial contacts and locations

1

Loading...

Central trial contact

Robert F Bonvini, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems